Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/16/2025

Thrombotic Arteriovenous Graft (AVG) Causes and Management

Primary Mechanism: Venous Stenosis

  • Venous outflow stenosis is the predominant precipitator of AVG thrombosis, causing increased intra-access pressure and decreased blood flow that ultimately leads to clot formation if untreated 1, 3
  • Unrecognized stenosis is the primary determinant of graft thrombosis rates, with baseline rates of 0.5-0.8 episodes/graft-year that can be reduced by 43-67% through surveillance programs 1
  • Hemodynamically significant stenosis is defined as ≥50% reduction in vessel diameter accompanied by clinical or physiologic abnormalities 4, 3

Secondary Contributing Factors

  • Diabetes mellitus significantly decreases prosthetic graft survival, even within the first 30 days 1, 7
  • Increasing age adversely affects graft patency in non-diabetic patients 1, 7
  • Hypertension and vascular disease contribute to access dysfunction 1
  • Patients with chronic kidney disease exhibit a prothrombotic state through multiple mechanisms including elevated fibrinogen, D-dimer, plasminogen activator inhibitor-1, and inflammatory markers 5, 6

Technical and Anatomic Factors

  • Primary failure within 30 days reflects surgical construction problems or inappropriate vessel selection rather than stenosis 1, 7
  • Inadequate pre-operative vascular assessment leads to suboptimal graft placement 7
  • Premature cannulation and hematoma formation can precipitate early thrombosis 1, 7

Clinical Recognition

  • Absence of bruit or thrill is highly predictive of thrombosis or severe stenosis 4
  • A palpable thrill indicates flow ≥450 mL/min; its absence warrants immediate evaluation 4
  • Arm swelling suggests venous outflow obstruction 4

Critical Management Implications

  • Thrombectomy must be performed within 48 hours for optimal outcomes when thrombosis occurs 4
  • Identification and treatment of ALL significant stenoses during thrombectomy is essential for long-term patency 2
  • After percutaneous thrombectomy, 3-month primary patency rates are only 30-40%, compared to 40-50% for preemptive PTA of non-thrombosed grafts 1, 2
  • Preemptive treatment of stenosis before thrombosis occurs yields superior outcomes: 71-85% of grafts remain intervention-free versus only 33-63% after thrombectomy 1

Common Pitfalls

  • Delaying evaluation of access dysfunction leads to thrombosis rather than allowing preemptive stenosis correction 3
  • Inadequate correction of stenosis during thrombectomy procedures results in rapid re-thrombosis 2
  • Not implementing systematic surveillance programs to detect stenosis before thrombosis occurs 1

REFERENCES

1

clinical practice guidelines for vascular access. [LINK]

American Journal of Kidney Diseases, 2006

2

Vascular Complications of AV Fistula Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Urgent Evaluation and Management of Arteriovenous Grafts with Absent Bruit [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4

clinical practice guidelines for vascular access. [LINK]

American Journal of Kidney Diseases, 2006

7

clinical practice guidelines for vascular access. [LINK]

American Journal of Kidney Diseases, 2006